Avience Biomedicals Ltd (AVIENCE) — shareholding pattern, promoter holding, financials and share price
About Avience Biomedicals Ltd (AVIENCE)
Avience Biomedicals Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as AVIENCE and on the BSE under scrip code 94324. Its ISIN is INE0V9I01017.
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions. [1]
Listed peers in Medical Equipment & Supplies: Nureca Ltd, Earkart Limited, QMS Medical Allied Services Ltd, Choksi Asia Ltd, Aakaar Medical Technologies Ltd, Royal Sense Ltd.
Valuation & Returns
10 Jul 2026At ₹277.75 a share on 10 Jul 2026, Avience Biomedicals Ltd (AVIENCE) was valued at a price-to-earnings ratio of 26.55x against an industry P/E of 44.11x and a price-to-book of 1.74x on a book value of ₹159.61 per share. Solomo computes return on equity of 20.13% and return on capital employed of 17.09% from filed results.
- P/E
- 26.55x
- Industry P/E
- 44.11x
- P/B
- 1.74x
- EPS (TTM)
- ₹10.46
- Book value / share
- ₹159.61
- ROE
- 20.13%
- ROCE
- 17.09%
- Debt / equity
- 0.94x
- Dividend yield
- 0%
- 52-week range
- ₹275 – ₹414.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Avience Biomedicals Ltd (AVIENCE) reported revenue of ₹41.84 crore, net profit of ₹5.74 crore and earnings per share of ₹14.24. That compares with revenue of ₹44.92 crore and net profit of ₹7.1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 23.83 | 44.92 | 41.84 |
| Net profit (₹ cr) | 2.16 | 7.1 | 5.74 |
| EPS (₹) | 6.58 | 17.61 | 14.24 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 41.73% | 88.81% |
| Profit growth | 90.96% | 228.70% |